Chitosan and chitosan nanoparticles as adjuvant in local Rift Valley Fever inactivated vaccine

• Published in: 3 Biotech Vol. 10; no. 3; p. 88
• Main Authors: El-Sissi, Ashgan F., Mohamed, Farida H., Danial, Nadia M., Gaballah, Ali Q., Ali, Korany A.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.03.2020; Springer Nature B.V
• Subjects: Adjuvants; Agriculture; Antibodies; Antigens; Bioinformatics; Biomaterials; Biotechnology; Cancer Research; Chemistry; Chemistry and Materials Science; Chitosan; Coccidioidomycosis; Gelation; Gene expression; Humerus; Immune response (cell-mediated); Immune system; Immunity; Immunization; Immunoglobulin G; Interleukin 2; Interleukin 4; Macrophages; Nanoparticles; Original; Original Article; Peritoneum; Phagocytes; Rift Valley fever; Stem Cells; Vaccines; Viral diseases; Viruses; γ-Interferon; Nanoparticles; Rift Valley Fever; Vaccine; Chitosan
• ISSN: 2190-572X; 2190-5738
• DOI: 10.1007/s13205-020-2076-y

The present study aimed to improve the potency of inactivated Rift Valley Fever Virus (RVFV) vaccine using chitosan (CS) or chitosan nanoparticles (CNP) as adjuvants. Chitosan nanoparticles were prepared by ionic gelation method. Rift Valley Fever Virus (RVFV) inactivated antigen was loaded on CS and CNP to form two vaccine formulations, RVFV-chitosan nanoparticles based vaccine (RVFV-CNP) and RVFV chitosan based vaccine (RVFV-CS). Five groups of mice were used in this study, each group was injected with one of the following: phosphate buffer saline (group1 G1), RVFV-CNP (G2), (RVF-CS) (G3), RVFV-Alum based vaccine (RVFV-Alum) (G4) and adjuvant free RVFV inactivated antigen (RVFV-Ag) (G5). The immunization was performed twice with 2 weeks interval. The results showed that, RVFV-CNP vaccine enhanced strongly the phagocytic activity of peritoneal macrophage (PM), neutralization antibodies titer against RVFV and IgG values against RVFV nucleoprotein than other vaccine formulations did. In addition, the RVFV-CNP and RVF-CS vaccines upregulate the gene expression of IL-2, IFN - γ (which promote cell mediated immunity) and IL-4 (which promote humeral immunity), while RVFV-Alum vaccine upregulate the gene expression of IL-4 only. These findings indicated that CS and CNP were comparable to the alum as adjuvant in efficacy but superior to it in inducing cell-mediated immune response and might be a candidate adjuvant for inactivated RVFV vaccine.